Vaccine News and Research

Latest Vaccine News and Research

CDC issues new guidelines on detection of Mycobacterium tuberculosis infections

Today the United States Centers for Disease Control and Prevention issued new and important guidelines on the detection of Mycobacterium tuberculosis infections, the causative agent of tuberculosis. In these landmark guidelines, CDC advises that Interferon Gamma Release Assay blood tests are now preferred over the 100+-year-old tuberculin skin test for diagnosing TB infection in certain populations, including people who typically do not return for the necessary reading of TST results, and those who have received Bacille Calmette-Guerin as a vaccine or for cancer therapy

1 Jul 2010

GeoVax Labs postpones proposed public offering

GeoVax Labs, Inc., a biotechnology company dedicated to developing vaccines that prevent and fight human immunodeficiency virus (HIV), today announced that it has decided to postpone its proposed public offering of units, each consisting of a share of common stock and a warrant to purchase another share.

1 Jul 2010

BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive

BioSante Pharmaceuticals, Inc. announced today positive results in a Phase II study of the Pill-Plus "triple hormone" oral contraceptive (OC). Results showed an increase in the frequency of sexual activity (p< 0.05) and reduced frequency of rejection of initiation of sexual activity by partner (p< 0.05).

30 Jun 2010

Original viral genetic sequences still present months after initial infection, says study

Scientists have been surprised to learn that, despite thousands of changes that viruses like HIV undergo in rapid fashion to evade the body's immune system, the original version that caused the infection is still present in the body months later.

30 Jun 2010

White House to release domestic strategy against AIDS

The White House is poised to release the country's first comprehensive domestic strategy against AIDS, as funds to prevent infections have failed to halt the epidemic in those most at risk of the disease, AIDS groups said. Release of the National AIDS Strategy may come as early as today, fulfilling Obama's campaign pledge to unify priorities among federal agencies and state partners, said Mitchell Warren.

30 Jun 2010

Greenwire/New York Times examine dengue vaccine development

Greenwire/New York Times reports on the growing number of cases of dengue worldwide, including the CDC's report last month that the virus has now been locally acquired in the continental U.S. for the first time in 65 years. "While a few cases were reported earlier, they were primarily in Americans who had caught the virus abroad or at the Texas-Mexico border," the news service writes.

30 Jun 2010

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

CEL-SCI Corporation and researchers at the Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM) jointly announced today that a LEAPS-based vaccine (Ligand Epitope Antigen Presentation System) study has demonstrated the technology's potential using dendritic cells to stimulate the immune system to fight viral illnesses and other diseases.

29 Jun 2010

Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announces a research collaboration with immatics biotechnologies GmbH to explore the development of novel ImmunoBody® vaccines for colorectal cancer.

29 Jun 2010

Health Canada recommends new pneumococcal vaccine for young children

In December, 2009, Health Canada approved a new vaccine for children aged six weeks through five years to prevent infections caused by the bacteria called pneumococcus or Streptococcus.

29 Jun 2010

Marine organisms may hold key to fight malaria

University of Central Florida scientist Debopam Chakrabarti is analyzing more than 2,500 samples from marine organisms collected off deep sea near Florida's coast. Some of them could hold the key to developing drugs to fight malaria, a mosquito-borne illness that kills more than 1 million people worldwide annually.

29 Jun 2010

MGH, Iacocca Foundation complete Phase I BCG clinical trial in type 1 diabetes

Massachusetts General Hospital (MGH) and the Iacocca Foundation announce today the completion of the Phase I BCG clinical trial in type 1 diabetes, as well as the submission of all safety reports to the U.S. Food and Drug Administration (FDA) and the MGH data safety monitoring boards. Plans for the Phase II clinical study, which will continue the investigation of bacillus Calmette-Guerin (BCG) vaccination as a treatment for people with existing type 1 diabetes, are actively underway.

29 Jun 2010

Rubella epidemic played a major role in shifting public attitudes toward abortion laws

Ten years before the 1973 Supreme Court decision legalizing abortion - which likely will be a focus of Senate confirmation questions for Supreme Court nominee Elena Kagan next week - German measles probably played the biggest part in starting to shift public attitudes about the criminal abortion laws, University of Illinois historian Leslie J. Reagan says in a new book.

29 Jun 2010

IAVI announces Japanese pledge of $10M for AIDS vaccine research and development

The International AIDS Vaccine Initiative (IAVI) announced today that the Government of Japan pledged a US$10 million grant to support AIDS vaccine research and development over the next five years. The grant, which will be channeled through a newly established World Bank trust fund, is the first of its kind from the Japanese government to IAVI.

28 Jun 2010

Inhibitex joins Russell 3000 Index

Inhibitex, Inc. announced today that the Company was added to the broad-market Russell 3000® Index, as well as its Microcap and Global Indexes, when Russell Investments reconstituted its comprehensive set of U.S. and global equity indexes on Friday June 25, 2010.

28 Jun 2010

BioSante joins Russell 3000 Index

BioSante Pharmaceuticals, Inc. today announced it has been added to the broad-market Russell 3000 Index as part of Russell Investments' recent reconstitution of its comprehensive set of U.S. and global equity indexes which occurred after market close on June 25, 2010.

28 Jun 2010

RiVax intradermal administration protects from mucosal, systemic ricin intoxication

Soligenix, Inc., a late-stage biopharmaceutical company, announced today the publication of an article in the June 2010 edition of Vaccine, which describes protection from mucosal and systemic ricin intoxication by intradermal administration of RiVax™, the Company's vaccine against ricin toxin.

28 Jun 2010

Combination MMRV vaccine associated with increased risk of febrile seizures

The combination vaccine for measles, mumps, rubella and chickenpox (MMRV) is associated with double the risk of febrile seizures for 1- to 2-year-old children compared with same-day administration of the separate vaccine for MMR (measles, mumps, rubella) and the varicella (V) vaccine for chicken pox, according to a Kaiser Permanente Division of Research study appearing online in the journal Pediatrics. A febrile seizure is a brief, fever-related convulsion but it does not lead to epilepsy or seizure disorders, researchers explained.

28 Jun 2010

WCO signs declaration, vows to crack down on counterfeit drug industry

World Customs Organization Secretary General Kunio Mikuriya on Thursday signed a declaration vowing his group's commitment to crack down on the counterfeit drug industry, PBS NewsHour's "The Rundown" blog reports. The piece examines the growing threat of counterfeit medications worldwide and efforts to clamp down on the distribution of such drugs (Miller, 6/24).

28 Jun 2010

Additional results from BLISS-76 Phase 3 trial of BENLYSTA presented at International Congress on SLE

Human Genome Sciences, Inc. today announced the presentation of additional results from BLISS-76, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus. The additional data will be presented in Vancouver at the 9th International Congress on Systemic Lupus Erythematosus on Friday and Saturday, June 25-26.

28 Jun 2010

Overview of scientific research on medical technology to combat anthrax threat

The 2001 anthrax attacks in the United States are fostering development of a new generation of vaccines, antibiotics, and other medications to protect people against the potentially deadly bacteria in any future bioterrorist incident. That's the conclusion of a sweeping overview of scientific research on medical technology to combat the anthrax threat. It appears in ACS' bi-weekly Journal of Medicinal Chemistry.

25 Jun 2010

Vaccine News and Research

Latest Vaccine News and Research

CDC issues new guidelines on detection of Mycobacterium tuberculosis infections

GeoVax Labs postpones proposed public offering

BioSante reports positive results from Phase II study of Pill-Plus "triple hormone" oral contraceptive

Original viral genetic sequences still present months after initial infection, says study

White House to release domestic strategy against AIDS

Greenwire/New York Times examine dengue vaccine development

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer

Health Canada recommends new pneumococcal vaccine for young children

Marine organisms may hold key to fight malaria

MGH, Iacocca Foundation complete Phase I BCG clinical trial in type 1 diabetes

Rubella epidemic played a major role in shifting public attitudes toward abortion laws

IAVI announces Japanese pledge of $10M for AIDS vaccine research and development

Inhibitex joins Russell 3000 Index

BioSante joins Russell 3000 Index

RiVax intradermal administration protects from mucosal, systemic ricin intoxication

Combination MMRV vaccine associated with increased risk of febrile seizures

WCO signs declaration, vows to crack down on counterfeit drug industry

Additional results from BLISS-76 Phase 3 trial of BENLYSTA presented at International Congress on SLE

Overview of scientific research on medical technology to combat anthrax threat

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Vaccine News and Research

Latest Vaccine News and Research

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in